Furan-2-carboximidsaeure-aethylester-hydrochlorid | 54610-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: Furan-2-carboximidsaeure-aethylester-hydrochlorid
• 英文别名: furan-2-carboximidic acid ethyl ester; hydrochloride；ethyl furan-2-carboximidate hydrochloride；2-Furancarboximidic acid, ethyl ester, hydrochloride；ethyl furan-2-carboximidate;hydrochloride
• CAS: 54610-51-4
• 化学式: C₇H₉NO₂*ClH
• 分子量: 175.615
• InChiKey: QGPKNFLXLAUPFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.06
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Furan-2-carboximidsaeure-aethylester-hydrochlorid 在 氨 作用下， 以 乙醇 为溶剂， 反应 72.0h， 生成 2-呋喃羧酰胺
  参考文献：
  名称：

  Inhibitors of human nitric oxide synthase isoforms with the carbamidine moiety as a common structural element

  摘要：

  Identification of potent and selective inhibitors of inducible nitric oxide synthase (NOS) is of great interest because of their therapeutic potential for treatment of diseases mediated by excess production of nitric oxide. We present here a comparison of potency and selectivity for amino acid and nonamino acid based compounds as inhibitors of human inducible, human endothelial constitutive and human neuronal constitutive NOS isoforms. In addition, a novel series of substituted amidines has been identified as NOS inhibitors. 2-Methylthioacetamidine and 2-thienylcarbamidine were the most potent of the series examined with IC50 values of 3.9 and 2.9 mu M for human neuronal constitutive NOS. Cyclopropylcarbamidine and 2-thienylcarbamidine were the most potent inhibitors for human inducible NOS with IC50 values of 5.2 and 6.5 mu M, respectively. These substituted amidines represent a new class of NOS inhibitors acid provide a foundation for potential therapeutic agents. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0968-0896(96)00148-4
• 作为产物：
  描述：

  2-氰基呋喃 、 乙醇 在 盐酸 作用下， 以 二氯甲烷 为溶剂， 生成 Furan-2-carboximidsaeure-aethylester-hydrochlorid
  参考文献：
  名称：

  One-flask synthesis of 1,3,5-trisubstituted 1,2,4-triazoles from nitriles and hydrazonoyl chlorides via 1,3-dipolar cycloaddition

  摘要：

  一瓶法合成1,3,5-三取代-1,2,4-三唑，从腈和叠氮酰氯通过1,3-偶极环加成。

  DOI：

  10.1039/c4ra00113c

文献信息

• Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors
  作者：Lucia Squarcialupi、Matteo Falsini、Daniela Catarzi、Flavia Varano、Marco Betti、Katia Varani、Fabrizio Vincenzi、Diego Dal Ben、Catia Lambertucci、Rosaria Volpini、Vittoria Colotta

  DOI：10.1016/j.bmc.2016.04.048

  日期：2016.6

  receptors (cAMP assays). Its 2-(2-hydroxybenzyl) analog 26 also showed a high affinity for the hA2A AR (Ki=5.26nM) and was 22-fold selective versus the hA1 subtype. Molecular docking investigations performed at the hA2A AR crystal structure and at a homology model of the hA1 AR allowed us to represent the hypothetical binding mode of our derivatives and to rationalize the observed SARs.

  合成了一系列新的7-氨基吡唑并[4,3-d]嘧啶衍生物（1-31），以评估2位和5位的一些结构修饰，旨在改变对人（h）A2A腺苷受体（ AR）或hA2A和hA1 ARs。活性最高的化合物是那些在位置5处带有2-呋喃基或5-甲基呋喃-2-基的化合物，在位置2处带有苄基或取代的苄基，其中一些衍生物（22-31）具有纳摩尔浓度对hA2A AR的亲和力（Ki = 3.62-57nM），对hA1 AR的亲和力略低，因此显示出相对于hA1选择性而言，hA2A的程度不同（3-22倍）。尤其是，2-（2-甲氧基苄基）-5-（5-甲基呋喃-2-基）衍生物25具有最高的hA2A和hA1 AR亲和力（Ki = 3.62nM和18nM，并在这两个受体上均表现出强大的拮抗作用（cAMP分析）。它的2-（2-羟基苄基）类似物26对hA2A AR也有很高的亲和力（Ki = 5.26nM），相对于hA1亚型具有22倍的选择性。在hA2A
• [EN] OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO<br/>[FR] COMPOSES OXAZOLIDINONE ET COMPOSITIONS ET METHODES ASSOCIEES
  申请人：FERRER INT

  公开号：WO2006010756A1

  公开（公告）日：2006-02-02

  The invention provides new oxazolidinones of formula (I), where R1, R2, R3 and R4 are independently selected from hydrogen, F and Cl; A is selected from certain heterocycles optionally substituted; X is selected from O, S, NRs and CR8Rg; Y is selected from O, S, SO, SO2, NO, NR11 and CR11R12; and n is selected from 0 and 1. The invention also provides different processes for the preparation of such compounds. Oxazolidinone compounds of formula (I) are active against Gram-positive and some Gram-negative human and veterinary pathogens with a weak monoamine oxidase (MAO) inhibitory activity. They are useful for the treatment of bacterial infections.

  该发明提供了新的氧氮杂环酮化合物，其化学式为（I），其中R1、R2、R3和R4分别选自氢、F和Cl；A选自某些可选取代的杂环；X选自O、S、NRs和CR8Rg；Y选自O、S、SO、SO2、NO、NR11和CR11R12；n选自0和1。该发明还提供了制备这类化合物的不同方法。化学式（I）的氧氮杂环酮化合物对革兰氏阳性和一些革兰氏阴性的人类和兽医病原体具有弱的单胺氧化酶（MAO）抑制活性。它们对细菌感染的治疗具有用处。
• Synthese von heterocyclen. V. 1, 3, 4-thiadiazol-2 (3H)-one
  作者：Haukur Kristinsson、Tammo Winkler

  DOI：10.1002/hlca.19820650833

  日期：1982.12.15

  A new and highly versatile method for the synthesis of 1, 3, 4-thiadiazol-2 (3 H)ones 1 is described. Methoxy-1,3,4-thiadiazoles- 5, which are readily available by condensation of O-methyl thiocarbazate (2) with acid derivatives 3, undergo an efficient cleavage to 1 and methyl chloride with hydrochloric acid in an anhydrous medium. Many new 5-substituted thiadiazolones, unavailable by earlier routes

  描述了一种合成1，3，4-噻二唑-2（3 H）ones 1的新方法，该方法用途广泛。甲氧基-1,3,4-噻二唑-5（可通过将O-甲基硫代氨基甲酸酯（2）与酸衍生物3缩合而容易获得）在无水介质中有效裂解为1，并用盐酸将其分解为氯甲烷。合成了许多新的5-取代的噻二唑酮，较早的途径无法获得。讨论了制备方面和机理方面。借助13 C-NMR。光谱学，1的互变异构研究表明，互变异构平衡取决于5-位取代基的性质。噻二唑酮1主要以氧代形式存在。然而，羟基形式的百分比随着在5-位的强烈吸电子取代基而增加。用对甲良好的相关性ķ一个观察和σ值- 。
• [EN] AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS<br/>[FR] DERIVES D'AMINO-PROPANOL COMME MODULATEURS DE RECEPTEUR DE SPHINGOSINE-1-PHOSPHATE
  申请人：NOVARTIS AG

  公开号：WO2004096757A1

  公开（公告）日：2004-11-11

  Compounds of formula (I), wherein X, a, b, R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

  式(I)的化合物，其中X、a、b、R1、R2、R3、R4和R5如规范中定义，它们的生产过程，用途以及含有它们的药物组合物。
• Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
  申请人：Albert Rainer

  公开号：US20060211656A1

  公开（公告）日：2006-09-21

  Compounds of formula I, wherein X, a, b, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

  公式为I的化合物，其中X，a，b，R1，R2，R3，R4和R5如规范中所定义，其生产过程，其用途以及含有它们的药物组合物。